These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
781 related articles for article (PubMed ID: 28361465)
1. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. Lambert JM; Morris CQ Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465 [TBL] [Abstract][Full Text] [Related]
2. Antibody-drug conjugates: present and future. Beck A; Reichert JM MAbs; 2014; 6(1):15-7. PubMed ID: 24423577 [TBL] [Abstract][Full Text] [Related]
3. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy. Jerjian TV; Glode AE; Thompson LA; O'Bryant CL Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352 [TBL] [Abstract][Full Text] [Related]
4. Antibody-Drug Conjugates for Cancer Treatment. Lambert JM; Berkenblit A Annu Rev Med; 2018 Jan; 69():191-207. PubMed ID: 29414262 [TBL] [Abstract][Full Text] [Related]
5. Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany. Beck A; Lambert J; Sun M; Lin K MAbs; 2012; 4(6):637-47. PubMed ID: 22909934 [TBL] [Abstract][Full Text] [Related]
6. Site-specific antibody drug conjugates for cancer therapy. Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR MAbs; 2014; 6(1):34-45. PubMed ID: 24423619 [TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Ricart AD Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069 [TBL] [Abstract][Full Text] [Related]
11. World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany. Beck A; Senter P; Chari R MAbs; 2011; 3(4):331-7. PubMed ID: 21691144 [TBL] [Abstract][Full Text] [Related]
12. Strategies and challenges for the next generation of antibody-drug conjugates. Beck A; Goetsch L; Dumontet C; Corvaïa N Nat Rev Drug Discov; 2017 May; 16(5):315-337. PubMed ID: 28303026 [TBL] [Abstract][Full Text] [Related]
13. Third-generation antibody drug conjugates for cancer therapy--a balancing act. Vankemmelbeke M; Durrant L Ther Deliv; 2016; 7(3):141-4. PubMed ID: 26893243 [No Abstract] [Full Text] [Related]
14. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer. Najjar MK; Manore SG; Regua AT; Lo HW Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360302 [TBL] [Abstract][Full Text] [Related]
15. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Baron JM; Boster BL; Barnett CM J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654 [TBL] [Abstract][Full Text] [Related]
16. The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin. Cianfriglia M Ann Ist Super Sanita; 2013; 49(2):150-68. PubMed ID: 23771260 [TBL] [Abstract][Full Text] [Related]
17. [Immunoconjugates, drug-armed antibodies to fight against cancer]. Haeuw JF; Caussanel V; Beck A Med Sci (Paris); 2009 Dec; 25(12):1046-52. PubMed ID: 20035677 [TBL] [Abstract][Full Text] [Related]
18. Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate. Marcoux J; Champion T; Colas O; Wagner-Rousset E; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S Protein Sci; 2015 Aug; 24(8):1210-23. PubMed ID: 25694334 [TBL] [Abstract][Full Text] [Related]
19. Drug-conjugated antibodies for the treatment of cancer. Lambert JM Br J Clin Pharmacol; 2013 Aug; 76(2):248-62. PubMed ID: 23173552 [TBL] [Abstract][Full Text] [Related]
20. The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors. Tarantino P; Tolaney SM Cancer Res; 2022 Oct; 82(20):3659-3661. PubMed ID: 36245247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]